Serbia

Population 2018 8.8 million

<table>
<thead>
<tr>
<th>Estimates of TB burden*, 2018</th>
<th>Number (thousands)</th>
<th>Rate (per 100 000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total TB incidence</td>
<td>1.5 (1.3–1.8)</td>
<td>17 (15–20)</td>
</tr>
<tr>
<td>HIV-positive TB incidence</td>
<td>&lt;0.01 (&lt;0.01–&lt;0.01)</td>
<td>0.06 (0.03–0.09)</td>
</tr>
<tr>
<td>MDR/RR-TB incidence°°</td>
<td>0.022 (0.01–0.039)</td>
<td>0.25 (0.11–0.45)</td>
</tr>
<tr>
<td>HIV-negative TB mortality</td>
<td>0.055 (0.05–0.061)</td>
<td>0.63 (0.57–0.69)</td>
</tr>
<tr>
<td>HIV-positive TB mortality</td>
<td>0 (0–&lt;0.01)</td>
<td>0.01 (0–0.02)</td>
</tr>
</tbody>
</table>

Estimated proportion of TB cases with MDR/RR-TB, 2018

- % tested with rapid diagnostics at time of diagnosis
- % with known HIV status
- % pulmonary
- % bacteriologically confirmed°°°
- % children aged 0-14 years
- % women
- % men

Total cases notified 1 358

Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2018 87% (75–100)

TB patients facing catastrophic total costs

TB case fatality ratio (estimated mortality/estimated incidence), 2018 4% (3–4)

TB/HIV care in new and relapse TB patients, 2018

Patients with known HIV status who are HIV-positive 8 14%
- on antiretroviral therapy 8 100%

Drug-resistant TB care, 2018

% of bacteriologically confirmed TB cases tested for rifampicin resistance °°°
- New cases 56%
- Previously treated cases 40%

Laboratory-confirmed cases* MDR/RR-TB: 3, XDR-TB: 0

Patients started on treatment* ** MDR/RR-TB: 1, XDR-TB: 0

MDR/RR-TB cases tested for resistance to second-line drugs 0

Treatment success rate and cohort size

New and relapse cases registered in 2017 86% 1 440
Previously treated cases, excluding relapse, registered in 2017 56% 18
HIV-positive TB cases registered in 2017 75% 8
MDR/RR-TB cases started on second-line treatment in 2016 70% 10
XDR-TB cases started on second-line treatment in 2016 0% 1

TB preventive treatment, 2018

% of HIV-positive people (newly enrolled in care) on preventive treatment

% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment

TB financing, 2019

National TB budget (US$ millions) 8.2

Funding source: 99% domestic, 0% international, 1% unfunded

° Ranges represent uncertainty intervals
°° MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
°°° Calculated for pulmonary cases only

* Includes cases with unknown previous TB treatment history
** Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.

Generated: 2020-04-22 Data: www.who.int/tb/data